The PD-L1 expression was positive in: 28.6% of melanoma, 22.4% of GC, 20.9% of CRC, 12.5% of BTC, 7.1% of GU cancer/miscellaneous tumors, 6.7% of HCC, 0.0% of pancreatic cancer, and 0.0% of sarcoma. This evidence concerns the gene CD274 and colorectal carcinoma.